Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HL04/WBP264 vs Avastin in non-squamous NSCLC
CTR20181297Phase 3Completed
- Sponsor
- Hualan Ankang Biotechnology
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Hualan Ankang Biotechnology. Started Aug 2018; status: completed.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20181297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181297.